Longeveron Inc. Segments Disclosure
13. Segment Information
Operating segments are defined as components of an entity for which discrete financial information is available and regularly reviewed by the Chief Operating Decision Maker (“CODM”) to allocate resources and assess performance. The Company’s , and the Company manages its operations as a operating segment focused on developing regenerative medicines to address unmet medical needs. The company’s measure of segment profit or loss is net loss. The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. are used to monitor budget versus actual results. All material long-lived assets of the Company are located in the United States and Company’s revenues are derived from the United States, the Bahamas and Israel. The total assets of the one reporting segment are disclosed on the balance sheets as of December 31, 2024 and 2023.
The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reportable segment:
|
|
Year Ended |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Revenues(1) |
|
$ |
2,392 |
|
|
$ |
709 |
|
Less: |
|
|
|
|
|
|
||
Cost of revenues |
|
|
508 |
|
|
|
488 |
|
R&D costs(2) |
|
|
2,799 |
|
|
|
5,704 |
|
G&A costs(3) |
|
|
5,646 |
|
|
|
6,869 |
|
Personnel costs(4) |
|
|
9,002 |
|
|
|
7,731 |
|
Other segment items(5) |
|
|
410 |
|
|
|
1,330 |
|
Net loss |
|
$ |
(15,973 |
) |
|
$ |
(21,413 |
) |
(1) Includes Contract Manufacturing and Clinical Trial revenue
(2) Includes Clinical Development, Research & Discovery, CMC
(3) Includes Executive, Finance, Legal, Business Operations
(4) Includes compensation, benefits and equity-based compensation
(5) Includes depreciation and amortization, (interest income) and other specific charges
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.